The Long-term Efficacy and Safety of Nilotinib in Pediatric Patients With CML: a 5-Year Update of the DIALOG Study.
The efficacy and safety of nilotinib in pediatric patients with imatinib/dasatinib resistant/intolerant (R/I) or newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) was demonstrated in the phase II, open-label DIALOG study...